Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.

IF 3.8 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2024-07-01 Epub Date: 2024-05-09 DOI:10.1007/s13300-024-01587-6

Luis A Vázquez, Santiago Tofé-Povedano, Diego Bellido-Guerrero, Marta Botella-Serrano, Alfonso Soto-González, Pedro Mezquita-Raya, Elías Delgado, Carmen Fajardo-Montañana, Cristóbal Morales-Portillo, Ana Causanilles, Miriam Rubio-de Santos, Irene Romera, Esteban Jódar-Gimeno

{"title":"Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.","authors":"Luis A Vázquez, Santiago Tofé-Povedano, Diego Bellido-Guerrero, Marta Botella-Serrano, Alfonso Soto-González, Pedro Mezquita-Raya, Elías Delgado, Carmen Fajardo-Montañana, Cristóbal Morales-Portillo, Ana Causanilles, Miriam Rubio-de Santos, Irene Romera, Esteban Jódar-Gimeno","doi":"10.1007/s13300-024-01587-6","DOIUrl":null,"url":null,"abstract":"<p><p>Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. It is approved in the USA and EU for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Due to the potential novelty represented by incorporating tirzepatide to clinical practice, we aim to review practical aspects of tirzepatide use in T2DM and the supporting scientific evidence. A group of ten endocrinologists involved as investigators in the phase 3 SURPASS clinical trial program followed a nominal group technique, a qualitative research methodology designed as a semi-structured group discussion to reach a consensus on the selection of a set of practical aspects. The scientific evidence for tirzepatide has been reviewed with respect to a number of patients' clinical profiles and care goals. Information of interest related to adverse events, special warnings and precautions, and other considerations for tirzepatide use has been included. Finally, information provided to the patients has been summarized. The practical aspects reported herein may be helpful in guiding physicians in the use of tirzepatide and contribute to optimizing the management of T2DM.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1501-1512"},"PeriodicalIF":3.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11211290/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-024-01587-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. It is approved in the USA and EU for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Due to the potential novelty represented by incorporating tirzepatide to clinical practice, we aim to review practical aspects of tirzepatide use in T2DM and the supporting scientific evidence. A group of ten endocrinologists involved as investigators in the phase 3 SURPASS clinical trial program followed a nominal group technique, a qualitative research methodology designed as a semi-structured group discussion to reach a consensus on the selection of a set of practical aspects. The scientific evidence for tirzepatide has been reviewed with respect to a number of patients' clinical profiles and care goals. Information of interest related to adverse events, special warnings and precautions, and other considerations for tirzepatide use has been included. Finally, information provided to the patients has been summarized. The practical aspects reported herein may be helpful in guiding physicians in the use of tirzepatide and contribute to optimizing the management of T2DM.

查看原文本刊更多论文

在成人 2 型糖尿病患者中使用替扎帕肽：科学证据与实践方面。

替扎帕肽是一种新型抗糖尿病药物，是葡萄糖依赖性促胰岛素多肽和胰高血糖素样肽-1受体的单分子激动剂。美国和欧盟已批准该药用于治疗 2 型糖尿病（T2DM）和肥胖症。由于将替扎帕肽应用于临床实践具有潜在的新颖性，我们旨在对替扎帕肽在 T2DM 中的实际应用和支持性科学证据进行回顾。由参与 SURPASS 3 期临床试验项目的十位内分泌专家组成的小组采用了名义小组技术，这是一种定性研究方法，旨在通过半结构化小组讨论，就一组实际问题的选择达成共识。针对一些患者的临床特征和护理目标，对替哌肽的科学证据进行了审查。此外，还纳入了与不良事件、特别警告和注意事项以及使用替扎帕肽的其他注意事项有关的相关信息。最后，还总结了向患者提供的信息。本文所报告的实际情况可能有助于指导医生使用替扎帕肽，并有助于优化 T2DM 的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.